

PRESS RELEASE

Hansa Biopharma to host conference call to provide half year results for January-June 2023 and a Business Update

Lund, Sweden, July 6, 2023 Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-June 2023 at 8:00 CET on July 20, 2023. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup, CCO and US President, Matthew Shaulis and CFO, Donato Spota. The presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under "Events & Presentations" and will also be made available online after the call. [Link to presentation](#)

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 10 884 80 16

United Kingdom: +44 20 3936 2999

United States: +1 646 664 1960

Participant access code: 323180

The webcast will be available on <https://events.q4inc.com/attendee/206699686>

Financial calendar and events 2023

July 18, 2023	William Blair Conference Transitioning Biotech Breakthroughs to Commercial Success (virtual)
July 20, 2023	Half-year Report for January-June 2023
Aug 23, 2023	Carnegie non-deal road show, Stockholm
Aug 24, 2023	Erik Penser Company Day, Stockholm
Aug 30-31, 2023	Cowen US non-deal road show
Sept 6-7, 2023	CITI Annual BioPharma Conference, Boston
Sept 11, 2023	HC Wainwright Annual Global Investment Conference, NYC
Sept 11-12, 2023	MorganStanley Global Healthcare Conference, NYC
Sept 14, 2023	Pareto Annual Healthcare Conference, Stockholm
Sept 14, 2023	Erik Penser Company Day, Malmö
Oct 2, 2023	Redeye: Autoimmune and inflammatory disease, Stockholm
Oct 12, 2023	Redeye: Afterwork, Malmö
Oct 19, 2023	Interim Report for January-September 2023
Nov 21, 2023	SEB Healthcare Seminar 2023, Stockholm
Nov 22, 2023	Ökonomisk Ugebrev Life Science Event, Copenhagen

For more information:

Klaus Sindahl, *VP Head of Investor Relations*

M: +46 (0) 709-298 269

E: klaus.sindahl@hansabiopharma.com

Stephanie Kenney, *VP Global Corporate Affairs*

M: +1 (484) 319 2802

E: stephanie.kenney@hansabiopharma.com

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at hansabiopharma.com.